Chicago-Treating localized prostate cancer with high-intensityfocused ultrasound (HIFU) appears to be safe, efficacious, and well tolerated,according to data presented by several European research groups at the AUAannual meeting in Chicago.
Initial results published for 177Lu-rhPSMA-10.1 in mCRPC
All patients treated with 177Lu-rhPSMA-10.1 had reductions in their PSA levels from the start of treatment and none experienced a serious treatment-related adverse event.
Dr. Schwen on focal therapies for prostate cancer
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
AUGS Position Statement: Vaginal Pessary Use and Management for Pelvic Organ Prolapse
The purpose of this clinical consensus statement is to identify areas of expert consensus and nonconsensus regarding pessary fitting, follow-up, and management of pessary complications to improve the safety and quality of care where evidence is currently limited.
Speaking of Urology: Liquid biopsy in prostate cancer
In this episode, David M. Albala, MD, and Sanoj Punnen, MD, discuss precision medicine and the use of biomarker tests in prostate cancer screening and detection.
How information blocking updates may affect your practice
"Urologists may wish to review their policies for patient portal, responding to requests for records, and supporting the concept of a shared electronic record," writes Robert A. Dowling, MD.
As Patients Live Longer, New Criteria Needed for Prostate Cancer Trials
Researchers sought to understand if a lack of cancer progression as monitored by radiography could substitute overall survival as a metric for metastatic prostate cancer clinical trials.
2 Commerce Drive Cranbury, NJ 08512